The CCS is actively recruiting cardiac care centres, cardiology clinics and cardiologists from across Canada to contribute to a pan-Canadian study about myocarditis and\/or pericarditis following mRNA COVID-19 vaccination.<\/p>\n\n\n\n
The CCS National Active Surveillance Study of Myocarditis and\/or Pericarditis following mRNA COVID-19 Vaccination (MYCOVACC) is a multi-centre study coordinated from the University of British Columbia under the leadership of Dr. Nathaniel Hawkins. MYCOVACC is funded by the Public Health Agency of Canada.<\/p>\n\n\n\n
MYCOVACC is assessing the outcomes of adult and pediatric patients with myocarditis and\/or pericarditis following mRNA vaccination for up to three years. Patients will be identified through Canadian cardiac care centres, public health authorities, and the study\u2019s research partners including COVID-VIHPR study sites.<\/p>\n\n\n\n
Study participants will be assessed at three months and 12 months after diagnosis and then annually for up to three years by a participating specialist using a clinical protocol based on the CCS 2021 Clinical Practice Update. They will also be invited to complete quality of life, mental health, physical activity, and health outcome questionnaires.<\/p>\n\n\n\n